Topical therapy in the treatment of actinic keratosis and basal cell carcinoma
被引:0
|
作者:
Newman, Marissa D.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Dermatol, Newark, NJ 07103 USAUniv Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Dermatol, Newark, NJ 07103 USA
Newman, Marissa D.
[1
]
Weinberg, Jeffrey M.
论文数: 0引用数: 0
h-index: 0
机构:Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Dermatol, Newark, NJ 07103 USA
Weinberg, Jeffrey M.
机构:
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Dermatol, Newark, NJ 07103 USA
[2] St Lukes Roosevelt Hosp, Dept Dermatol, New York, NY USA
[3] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA
[4] Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA
Actinic keratosis (AK) is an evolving malignant cutaneous neoplasm. AK also is known as solar keratosis and squamous cell carcinoma (SCC) in situ, either solar keratotic type or keratinocytic intraepidermal neoplasia. AKs can be treated with destructive or topical therapies. This article reviews current and evolving topical therapeutic options for AKs, several of which have been shown to offer substantial benefit in the alleviation of these lesions. The topical therapies include 5-fluorouracil (5-FU), diclofenac sodium, colchicine, retinoids, and imiquimod. Topical treatment of basal cell carcinoma (BCC) with imiquimod also will be discussed.